Renal endpoints such as estimated glomerular filtration rate (eGFR) slope, proteinuria reduction, and composite renal outcomes are central to nephrology clinical development. They are widely used across chronic kidney disease (CKD) and immune-mediated nephropathies and are supported by extensive clinical and regulatory experience. Despite this, these endpoints are frequently cited as limiting factors in renal trials, particularly because of variability, sensitivity to background therapy, and the long follow-up required to demonstrate treatment effects [1, 2].
In practice, many challenges attributed to renal endpoints arise not from the measures themselves, but from how they are incorporated into trial design and executed across heterogeneous clinical settings. Baseline instability, differences in standard-of-care therapy, and variability in site execution can meaningfully influence endpoint performance and ultimately shape trial outcomes [3].
This article examines commonly used renal endpoints from a design and execution perspective, focusing on where operational and methodological decisions influence signal detection. The discussion is centered on nephrology, with urologic considerations addressed where renal and genitourinary pathways intersect.
eGFR Slope as a Longitudinal Endpoint
eGFR slope is widely used in CKD development because it reflects longitudinal changes in kidney function and correlates with progression to kidney failure. scientific consensus, including work conducted in collaboration with the U.S. Food and Drug Administration, has recognized its utility when trials are designed with sufficient duration and appropriate statistical rigor [1,2].
At the same time, eGFR slope is sensitive to several operational factors that require careful consideration. Early hemodynamic effects following treatment initiation can influence short-term trajectories, particularly for therapies that affect intraglomerular pressure. If these effects are not anticipated during design, early changes may complicate interpretation of longer-term slope estimates.
Visit timing and laboratory consistency further influence slope calculations. Variability in serum creatinine measurement, missed or delayed visits, and differences in laboratory calibration can disproportionately affect slope-based analyses in long-duration studies.
Background therapy is another important contributor to variability. Contemporary CKD populations are commonly treated with renin–angiotensin system inhibitors, sodium–glucose cotransporter 2 inhibitors, and mineralocorticoid receptor antagonists. These therapies alter renal hemodynamics and disease progression and can attenuate observable differences between treatment arms when background use is heterogeneous across sites or regions [4].
These considerations do not diminish the value of eGFR slope as an endpoint. Rather, they underscore the need for deliberate planning around visit schedules, laboratory standardization, and background therapy documentation.
Proteinuria and Albuminuria Endpoints
Proteinuria and albuminuria reduction remain central endpoints in immune-mediated renal diseases such as IgA nephropathy and lupus nephritis. Their biological relevance and responsiveness to therapy make them particularly useful in earlier-phase development and in diseases where long-term renal outcomes require extended follow-up [3].
However, proteinuria endpoints are influenced by several sources of variability. Regression to the mean is a well-recognized phenomenon, particularly in studies enrolling patients during periods of heightened disease activity. Without adequate baseline confirmation, early reductions may reflect natural fluctuation rather than treatment effect [5].
Measurement methodology also plays a critical role. Differences in urine collection practices, patient adherence, and timing relative to medication administration introduce variability that cannot be fully addressed through central laboratory analysis alone. Proteinuria is also sensitive to concomitant therapies, including corticosteroids, immunosuppressive agents, and antihypertensive medications.
When background treatment is not standardized or systematically captured, changes in proteinuria may be difficult to attribute confidently to the investigational therapy. As with eGFR slope, disciplined execution is essential for reliable interpretation.
Composite Renal Endpoints
Composite renal endpoints are frequently used to capture clinically meaningful disease progression while improving statistical efficiency. Typical components include sustained declines in eGFR, initiation of dialysis, kidney transplantation, and renal death [2].
While composites offer practical advantages, they also introduce interpretive complexity. Individual components may be influenced by distinct biological and clinical factors. For example, initiation of dialysis is affected not only by disease progression but also by local practice patterns, healthcare access, and physician judgment.
The relative contribution of individual components may change over time, with softer components accumulating earlier and harder outcomes emerging later. In trials with limited follow-up, this imbalance can complicate interpretation. Composite endpoints are therefore most informative when their structure and expected event distribution are considered carefully during trial design rather than addressed post hoc.
Baseline Definition and Stability
Baseline definition is a critical, yet often underappreciated, determinant of endpoint performance in nephrology trials. Kidney function and proteinuria fluctuate in response to acute illness, medication changes, and disease activity, particularly in immune-mediated nephropathies [3].
Single time-point baselines may not adequately reflect underlying disease status. In conditions such as lupus nephritis, baseline measurements are often influenced by induction therapy, corticosteroid initiation or tapering, and recent disease flares. Without alignment between baseline timing and disease biology, early changes may reflect treatment transitions rather than investigational drug effects.
Baseline instability introduces bias that cannot be fully corrected through statistical adjustment. Confirmation periods, standardized timing, and explicit protocol guidance are therefore essential to support interpretable comparisons.
Rare Renal Diseases and Small-Population Studies
Rare renal disease trials present distinct methodological and operational challenges. Small sample sizes increase sensitivity to missing data, protocol deviations, and assay variability. In these settings, even limited inconsistency can materially affect outcomes [6].
Specialized referral centers facilitate access to eligible patients but may also introduce variability related to local practice patterns and aggressive disease management. High levels of clinical expertise do not necessarily translate into uniform protocol execution.
Biomarker enrichment strategies are frequently employed to target specific disease mechanisms. While enrichment can improve biological relevance, it may amplify variability if assays are immature or insufficiently standardized [8]. In small studies, trial robustness depends heavily on minimizing avoidable variability through disciplined execution.
Urologic Considerations Relevant to Renal Trials
Urology intersects with nephrology in conditions such as obstructive uropathy, nephrolithiasis, and surgical or procedural interventions that affect renal function. Urologic trials often rely on functional endpoints, imaging, and patient-reported outcomes, many of which are influenced by operator technique and assessment methodology.
When renal endpoints are included in genitourinary studies, coordination between nephrology and urology workflows is important to ensure consistent execution and interpretation.
Execution Considerations Across the Study Lifecycle
Across nephrology and urology trials, several execution factors consistently influence endpoint performance:
- Consistency in laboratory and pathology workflows
- Standardization of visit timing and assessment procedures
- Documentation and management of background therapy
- Anticipation and handling of intercurrent events
- Strategies to minimize missing data over long follow-up periods
Addressing these factors requires integration of medical, operational, and data oversight throughout the study lifecycle.
Implications for Trial Design and Interpretation
Challenges often attributed to renal endpoint limitations reflect broader issues related to baseline definition, site selection, execution consistency, and long-term follow-up [3].
Early identification of sources of variability, realistic feasibility assessment, and disciplined execution can materially improve interpretability of renal trial results, particularly in programs where treatment effects are incremental and require sustained observation.
Conclusion
Renal endpoints remain appropriate and necessary tools for evaluating disease progression and therapeutic benefit in nephrology. Their limitations are well recognized, but their performance depends heavily on how they are implemented within complex clinical and operational environments [1, 2].
Trials that prioritize baseline stability, manage background therapy variability, and execute endpoints consistently are better positioned to generate interpretable results. As nephrology development continues to evolve, success will depend not only on scientific innovation but also on disciplined execution and thoughtful endpoint use.
References
- Levey AS, Inker LA, Matsushita K, et al.
GFR decline as an end point for clinical trials in CKD: a scientific workshop sponsored by the National Kidney Foundation and the U.S. Food and Drug Administration. Am J Kidney Dis. 2014;64(6):821–835. - Levey AS, Coresh J, Inker LA, et al.
Change in albuminuria and GFR as end points for clinical trials in early stages of CKD: a scientific workshop sponsored by the National Kidney Foundation in collaboration with the U.S. Food and Drug Administration and European Medicines Agency. Am J Kidney Dis. 2020;75(1):84–104. - Barratt J, Rovin BH, Cattran D, et al.
Why target the gut to treat IgA nephropathy? Lancet. 2020;395(10235):1199–1200. - Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al.
Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436–1446. - Greene T, et al.
Regression to the mean and variability in proteinuria measurements. J Am Soc Nephrol. 2006;17(6):1615–1622. - Cattran DC, et al.
Clinical trial design in focal segmental glomerulosclerosis. Kidney Int. 2015;87(1):17–23. - Kidney Disease: Improving Global Outcomes
KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013;3(1):1–150. - Parikh CR, Coca SG, Thiessen-Philbrook H, et al.
Postoperative biomarkers predict acute kidney injury and poor outcomes. N Engl J Med. 2011;365(21):1929–1937.